نتایج جستجو برای: dolutegravir
تعداد نتایج: 953 فیلتر نتایج به سال:
A new dinuclear complex, [Ni(2)(H(2)O)L(4)].5H(2)O, consisting of chelating bidentate and bridging tridentate coordinated 2-[(4-methylphenylimino)methyl]-6-methoxyphenol (HL) Schiff base ligands and water molecules has been synthesized using a traditional method. The structure of this complex was characterized by FTIR and UV/Vis spectroscopy and thermogravimetric analyses (TG-DTG) and further c...
BACKGROUND There is concern over increasing prevalence of non-nucleoside reverse-transcriptase inhibitor (NNRTI) resistance in people initiating antiretroviral therapy (ART) in low-income and middle-income countries. We assessed the effectiveness and cost-effectiveness of alternative public health responses in countries in sub-Saharan Africa where the prevalence of pretreatment drug resistance ...
BACKGROUND Dolutegravir (S/GSK1349572), a once-daily, unboosted integrase inhibitor, was recently approved in the United States for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in combination with other antiretroviral agents. Dolutegravir, in combination with abacavir-lamivudine, may provide a simplified regimen. METHODS We conducted a randomized, double-blind, phase...
Background: Dolutegravir-based therapy was rolled-out in Kenya 2017 with limited safety studies the country and Africa. This study sought to assess profile adverse drug reactions, acceptability, adherence newly rolled out dolutegravir-based regimens among HIV patients attending Kenyatta National Hospital.Methods: a cross-sectional conducted between November December 2019 at national hospital co...
BACKGROUND Antiretroviral agents pose a high risk for drug-drug interactions (DDIs), mainly but not limited to being a substrate, inducer or inhibitor of P450 cytochrome enzymes. In part metabolised by other pathways, integrase inhibitors might show a more favourable profile. The aim of this study was to investigate the prevalence of DDIs in daily clinical practice for patients starting differe...
Drug-induced liver injury related to Triumeq (abacavir/lamivudine/dolutegravir) has not been reported in clinical trials. We report a case of hepatotoxicity related to Triumeq exposure in a human immunodeficiency virus-infected patient. Clinicians should remain aware of the risk for acute and late-onset hepatitis with these agents. Close monitoring is recommended.
In the past 25 years, the antiretroviral management of HIV-infection has revolutionised the prognosis of people with HIV. From a universally fatal illness in its fi rst decade, HIV has become a readily manageable disorder. In settings where access to antiretroviral therapy is subsidised, the prognosis for good health of a person with HIV can be measured in decades. Eff ective antiretrovirals ar...
INTRODUCTION The Antiretroviral Analysis by Monte Carlo Individual Simulation (ARAMIS) model was adapted to evaluate the cost-effectiveness of dolutegravir (DTG) in Canada in treatment-naive (TN) and treatment-experienced (TE) human immunodeficiency virus (HIV)-1 patients. METHODS The ARAMIS-DTG model is a microsimulation model with a lifetime analytic time horizon and a monthly cycle length....
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید